Risk Partners Life Sciences Roundtable 2024, thank you very much! Sign up now for the 26.06.2025 >

Contact us

We congratulate Steyr Motors AG on the successful listing
in the Scale Segment of the German Stock Exchange on October 30, 2024!

Risk Partners had the honor to act as IPO underwriting counsel in this transaction. Our team, led by Florian Eckstein and Björn Stressenreuter, supported Steyr Motors AG in its IPO on the Frankfurt Stock Exchange. Our expertise and comprehensive support were geared towards providing Steyr Motors with a secure and successful start on the capital markets.

We would like to thank Julian Cassutti and Christoph Cerar from Steyr Motors and the team at Mutares SE & Co. KGaA for the successful cooperation and their trust in our expertise.

With this step, Steyr Motors AG has not only gained access to additional capital for further growth, but has also strengthened its position as an innovation leader in the field of engine technology. 

About the Scale Segment of Deutsche Börse

Deutsche Börse's Scale segment offers small and medium-sized companies more straightforward access to the capital market and facilitates the financing of innovation and growth projects. Companies in the Scale segment benefit from a standardized listing process and special advisory networks that help them to master the challenges of the capital market with confidence.

At Risk Partners, we pride ourselves on supporting companies like Steyr Motors AG with specialized insurance solutions and comprehensive advice. From management liability insurance to innovative insurance products specifically tailored to the challenges and opportunities of an IPO, we offer customized solutions for our clients. When going public on a German stock exchange or through our innovative public flip concept when going public on a foreign stock exchange.

Ready for the next step?

For companies that are also looking to go public, Risk Partners offers tailor-made insurance solutions and advice to make this step a safe one. Contact us to find out how we can support you on your journey to the stock market.

Also read our other blog posts

Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
June 7, 2024
Being Public

New SEC Ruling: Transatlantic convergence in dealing with cyber security incidents

Foreign Filers / Private Issuers watch out! 2023 brought further harmonization of European and US standards for cyber incident reporting. According to the SEC Ruling, all companies listed on the US stock exchange are now required to publicly report significant data security incidents to the SEC within four working days. In addition, they must outline in their annual report (10-K) their procedures for identifying and addressing material cybersecurity risks, including the role of the board of directors. Note: This rule also applies to foreign private issuers (e.g., German companies that issue a

Read more "
January 17, 2024
Being Public

Revolution in D&O insurance in Nevada (US insurance market) postponed

The revolution in D&O insurance in Nevada has been called off after all. In the US market, the state of Nevada passed an interesting law (Bill No. 398) in the summer with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as too watchful for our clients, but this law

Read more "
December 9, 2023
Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
April 19, 2024
Venture Capital

We provide information on liability risks for VC funds in the VC Magazine

In December, we were asked by VC-Magazin whether we could provide insights into liability and risk management issues relating to venture capital funds. With pleasure! Together with the team, Florian not only provided insights into current challenges, but also suggested practical solutions to effectively minimize and sensibly transfer the risks of a VC fund. In the VC Magazine article, you will therefore find: added value of customized insurance concepts for VC funds (focus: D&O/E&O insurance #Moonshot Protect), key measures for risk prevention (learning curve from our claims world), indemnifying contractual provisions as a preventive measure, and

Read more "
January 26, 2024
Being Public

Risk Partners supports successful uplisting of Formycon AG to the Prime Standard

Congratulations to Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024! Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the Scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the field of biosimilars! Formycon AG has focused on

Read more "
November 14, 2024